688621.SH
阳光诺和
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 65.00
−1.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 1.2B | 1.1B | 932.1M | 676.6M |
| Cost of Revenue | 537.3M | 560.8M | 537.3M | 403.8M | 301.1M |
| Gross Profit | 651.2M | 661.4M | 541.1M | 528.3M | 375.5M |
| Operating Expenses | |||||
| R&D Expense | 159.3M | 161.6M | 171.9M | 123.7M | 89.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 157.4M | 140.9M | 106.3M | 109.4M | 90.5M |
| Selling & Marketing Expense | 55.0M | 52.7M | 44.1M | 43.8M | 20.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 387.7M | 371.8M | 334.9M | 283.2M | 205.3M |
| Cost and Expenses | 925.0M | 932.6M | 872.2M | 686.9M | 506.5M |
| Operating Income (EBIT) | 206.0M | 211.9M | 177.7M | 194.2M | 169.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 201.9M | 208.8M | 176.0M | 193.4M | 169.1M |
| Income Tax Expense | 327.3K | (1.8M) | 7.0M | 10.5M | 10.4M |
| Bottom Line | |||||
| Net Income | 194.9M | 203.9M | 177.4M | 184.8M | 156.5M |
| Earnings from Cont. Ops | 201.6M | 210.5M | 169.0M | 182.9M | 158.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 194.9M | 203.9M | 177.4M | 184.8M | 156.5M |
| Per Share | |||||
| Basic EPS | CN¥1.77 | CN¥1.86 | CN¥1.58 | CN¥1.65 | CN¥1.40 |
| Diluted EPS | CN¥1.77 | CN¥1.86 | CN¥1.58 | CN¥1.65 | CN¥1.40 |
| Revenue Per Share | CN¥10.37 | CN¥11.15 | CN¥9.60 | CN¥8.32 | CN¥6.05 |
| Shares | |||||
| Basic Shares Outstanding | 114.6M | 109.6M | 112.3M | 112.0M | 111.8M |
| Diluted Shares Outstanding | 114.6M | 109.6M | 112.3M | 112.0M | 111.8M |
| Profitability Metrics | |||||
| EBITDA | — | 260.9M | 223.2M | 236.7M | 200.3M |
| D&A | — | 49.1M | 45.5M | 42.5M | 31.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026